AstraZeneca has licensed Jacobio Pharma’s experimental pan-KRAS inhibitor JAB-23E73 in a deal worth up to $2.015 billion, announced on December 21, 2025. The UK pharma giant gains exclusive rights outside China, while both firms collaborate there. Early Phase I trials show anti-tumor promise in KRAS-mutated cancers affecting 23% of patients.
Deal Details Unveiled
Jacobio Pharma, a Hong Kong-listed biotech, revealed the licensing agreement on December 21, 2025. AstraZeneca pays $100 million upfront and offers up to $1.915 billion in milestones plus royalties on sales outside China. AstraZeneca handles global development and commercialization beyond China, speeding up the drug’s path to patients.
The pact targets JAB-23E73, a pan-KRAS inhibitor from Jacobio’s induced allosteric platform. This drug binds KRAS in active and inactive states, sparing HRAS and NRAS for better safety. Preclinical data show strong anti-tumor effects in KRAS-driven models without major toxicity.
KRAS Mutations: A Major Cancer Driver
KRAS ranks as the top mutated oncogene in cancers, hitting about 23% of cases worldwide. It fuels aggressive tumors in pancreas (90% mutated), colorectum (40%), and lung (30%). These mutations lock KRAS in an active state, spurring uncontrolled cell growth and resisting standard therapies.
Patients face grim outcomes. Pancreatic cancer survival sits below 10% at five years, partly due to KRAS. Pan-KRAS drugs like JAB-23E73 aim to block multiple subtypes (G12D, G12V, G12C), unlike earlier narrow inhibitors. Early trial signs of tumor shrinkage spark hope for broader impact.
JAB-23E73 Development Progress
Phase I trials for JAB-23E73 run in China and the US for advanced KRAS-altered solid tumors. Over 600 patients may enroll across studies, testing safety, dosing, and early efficacy. Preclinical work at AACR-NCI-EORTC 2025 showed potent activity and good oral pharmacokinetics.
Jacobio presented data in October 2025, highlighting tumor regression in mouse models. No major weight loss occurred, suggesting a wide safety window. The drug curbs p-ERK signaling in tumors, a key KRAS pathway marker.
| JAB-23E73 Clinical Trials Overview | |||
| Trial Phase | Locations | Focus | Status |
| Phase I/IIa | China, US | KRAS-mutated solid tumors | Recruiting (600+ patients targeted) |
| Dose Escalation | Multiple sites | Safety, PK, anti-tumor activity | Ongoing with early signals |
AstraZeneca’s Strategic Oncology Push
AstraZeneca bolsters its KRAS lineup with this deal. It follows a 2023 license of a KRAS G12D inhibitor from Usynova for $24 million upfront. Earlier, in-house KRAS G12C work led to AZD4625 and AZD4747, now in trials.
The firm eyes $80 billion oncology revenue by 2030. Matt Hellmann, SVP of Early Oncology R&D, called KRAS vital for unmet needs in pancreatic, colorectal, and lung cancers. Pairing JAB-23E73 with AstraZeneca’s portfolio could yield new combos.
| AstraZeneca KRAS Assets Comparison | ||||
| Drug | Target | Stage | Origin | Notes |
| JAB-23E73 | Pan-KRAS (ON/OFF) | Phase I/II | Jacobio (licensed) | Ex-China rights; $2B potential |
| AZD4747 | KRAS G12C | Phase II | In-house | Oral inhibitor |
| AZD0022 | KRAS G12D | Discontinued (Phase I) | Usynova (licensed) | Narrower scope |
Jacobio Pharma’s Rise in Oncology
Founded in 2015 in Beijing, Jacobio focuses on innovative cancer drugs via allosteric platforms. R&D hubs span Beijing, Shanghai, and Boston, with trials at 180+ China sites, 30+ US, and 10+ in Europe. Leadership, including Co-CEO Yinxiang Wang, Ph.D., pioneered China’s first targeted anti-cancer drug in 2003.
Jacobio’s pipeline stresses KRAS and STING pathways. Past deals include AbbVie for SHP2 (returned later). Shares surged 600% year-to-date pre-deal but dipped 14% post-announcement on valuation concerns.
Wang hailed the AstraZeneca tie-up as a global leap. It funds further KRAS work, tADCs, and immuno-oncology like STING iADCs.
Competitive Landscape in Pan-KRAS Space
Pan-KRAS inhibitors crowd the field, with 11+ clinical assets. Revolution Medicines leads with Phase III daraxonrasib (pan-RAS ON). Others include Pfizer’s PF-07934040, Lilly’s LY4066434, and Erasca’s ERAS-4001.
China firms shine: GenFleet’s GFH276 (Phase I/II), Hyperway’s HBW-016 (Phase II). AstraZeneca’s move catches peers like Roche, Amgen. Supply may exceed demand, pressuring valuations.
| Key Pan-KRAS Inhibitors in Clinic | |||
| Drug | Company | Stage | Notes |
| Daraxonrasib | Revolution Medicines | Phase III | Pan-RAS; pancreatic/lung focus |
| JAB-23E73 | Jacobio/AstraZeneca | Phase I/II | High selectivity; oral |
| PF-07934040 | Pfizer | Phase I | KRAS-mutated solids |
| ERAS-4001 | Erasca | Phase I | From Joyo; Borealis-1 trial |
Market Impact and Patient Outlook
The deal validates China biotechs in global oncology. Jacobio gains cash for pipeline acceleration; AstraZeneca fills pan-KRAS gap. Stock reactions highlight investor scrutiny on upfront sums amid competition.
For patients, success could transform KRAS-driven cancers. Trials target pancreatic, colorectal, NSCLC—high-burden diseases. Combos with immunotherapy or chemo may boost response rates beyond 20-30% seen in G12C drugs.
Final Thoughts
This $2B pact signals a KRAS therapy boom, blending AstraZeneca’s reach with Jacobio’s innovation. Watch Phase I/II data in 2026 for efficacy signals. Broader adoption hinges on beating rivals and proving combos; patients stand to gain most from faster approvals.
